Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is of dominant autosomal inheritance. Pathologic changes of vascular walls cause recurrent episodes of bleeding from many organ systems. Recurrent epistaxis is the first and the most frequent symptom of HHT. The causal therapy is not known but there are many therapeutic procedures improving the overall condition.
INTRODUCTION
Rendu-Osler-Weber syndrome or hereditary haemorrhagic telangiectasia is of dominant autosomal inheritance (1) . This rare systemic fibrovascular dysplasia causes an alteration in the elastic and muscle layers of vessel walls, making them more vulnerable to spontaneous ruptures and injuries (1) . Mucocutaneous teleangiectases, arteriovenous malformations, and recurrent spontaneous ruptures of vessels causing repeated bleeding are the most characteristic symptoms. HHT is spread worldwide; the prevalence varies between countries (2). The highest frequency of HHT is in the Netherlands Antilles (1:1331) (2), recent epidemiologic studies in Japan, France, and Denmark showed the incidence of 1:5,000 -1:8,000 (3) .
Several mutations in 2 genes, endoglin on chromosome 9 (HHT type 1) and activin receptor-like kinase-1 on chromosome 12 (HHT type 2), are associated with HHT (2) .
Teleangiectases are mainly localized in the mucosa of the nasal and oral cavity, gastrointestinal system, and in the skin of fingertips. Arteriovenous malformations occur mostly in lungs, liver, and central nervous system (4) . Teleangiectases in face, hands, and oral cavity occur approximately between the ages of 30 and 40 (4) . The first and most frequent symptom of the disease is recurrent epistaxis which occurs approximately in the 12th year of life, the frequency and intensity of bleeding increases with age (4). Severity of epistaxis varies widely from mild self-limited nosebleeds to severe life-threatening nasal haemorrhage (5) .
The clinical diagnosis of HHT is based on the Curaçao criteria. Three out of four criteria are required for a definite clinical diagnosis of HHT, two criteria are considered "possible" HHT, and 0 or 1 criterion makes the diagnosis unlikely (6) . The four Curaçao criteria include epistaxis, teleangiectases, mainly on the hands, face, and in the mouth, arteriovenous malformations in major organ systems and a family history of HHT (7) .
Several therapeutic approaches have been investigated but they are mostly palliative and have had variable results (8) . Treatments for HHT range from medication and conservative management to more aggressive surgeries (9) .
A range of interventions can be performed including nasal packing, hormone therapies, monoclonal antibodies, local sclerotherapy, diathermy, and coagulation or cautery techniques (10) .
The Nd:YAG laser coagulation and argon -plasma coagulation is usually the first option for patients with HHT (11) . Other therapeutic modalities include fibrin glue application, transarterial embolization, brachytherapy, ligation of arteries supplying nasal cavity and insertion of nasal obturators (12, 13, 14, 15, 16) .
Pharmacological Management of recurrent epistaxis also includes Bleomycine injections and Thalidomide administration (17, 18) .
Systemic pharmacological therapies, such as low-dose monoclonal humanized antibody bevacizumab, have been explored in recent years with evidence of benefit for patients seeking a non invasive treatment of severe epistaxis prior to considering surgical intervention (18) .
Surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia (HHT) has historically been managed with the laser procedure or the septodermoplasty procedure. For transfusion-dependent patients with severe epistaxis we have been performing the Young's procedure or surgical closure of the nostrils (19) .
Permanently closing the nares is thought to be effective because it protects the fragile intranasal telangiectasias from the drying effects of air flow (10) .
CASE REPORT During last ten years a 76-year-old man have been regularly referred to our clinic for massive bilateral epistaxis. At the age of 20 recurrent epistaxis connected with physical exertion occurred. The frequency and intensity of epistaxis increased with age. Similar symptoms had been present in the patient's father who died at age of 69 following a massive nose bleeding. Our patient had no children, one sister who suffered from an infrequent mild epistaxis. She had two children -30-and 31-year-old, respectively, neither with any symptom of the disease.
Over the last 10 years, the frequency and intensity of epistaxis grew, the nose bleeding returned approximately once a month. Generally, nasal package was the only way to stop it. Unfortunately, epistaxis returned almost after each removal of the package; after the first treatment the anterior nasal package had to be reinserted 6 or 7 times. Epistaxis was connected with massive blood loss, blood and plasma transfusions were always essential. The bleeding started spontaneously, usually during the evening while in a hori zontal position. The frequency of the blood transfusions administration is shown in Table 1 .
The frequency of the local treatment -the insertion of anterior nasal packages -is shown in Table 2 . Our patient had numerous telangiectases in the facial region, oral cavity, and hands, especially fingers.
A C T A M E D I C A M A R T I N I A N
Endoscopy of the gastrointestinal tract showed numerous teleangiectases spread from the distal half of oesophagus to duodenum.
CT scans of the lungs detected interstitial pulmonary process, presumably caused by diffuse pulmonary arteriovenous malformations, ultrasonography of the liver concerned diffuse lesion and haemangioma. CT examination of the brain showed the postmalatic pseudocyst localized in the frontal and parietal lobe. The size of the cyst was 44 × 26 × 22 mm.
The shape of the patient's external nose was markedly changed due to the frequent insertion of nasal package; the common meatus of the nasal cavity was dilated bilaterally. The nasal septum wasn't perforated. However, its frontal part was formed solely by mucosa without the cartilage. The mucosa of the nasal cavity was pale with numerous red teleangiectases.In addition to numerous nasal packages, selective arterial embolization was performed repeatedly. First, in June 2010, the left superior labial artery and the left sphenopalatine artery were embolized. Next, in September 2010, the embolization of the left sphenopalatine artery was performed again and in December 2011, facial artery on the left side and sphenopalatine artery on the right side were embolized. This therapeutic modality had no efficacy, the frequency and intensity of epistaxis remained unchanged. Next, numerous nasal packages, sometimes connected with electrocoagulation in cases of moderate bleeding, were performed. The patient died at the age of 76.
A C T A M E D I C A M A R T I N I

DISCUSSION
As already mentioned, recurrent epistaxis is the main symptom of hereditary haemorrhagic telangiectasia. Nowadays, Nd:YAG laser coagulation and argon -plasma coagulation is the first treatment for patients with this diagnosis (11) . This therapy, performed in local anaesthesia, is well tolerated by patients.
According to recent studies, low dose of Thalidomide seems to be safe and effective for the reduction of epistaxis. However, further studies are necessary. Unfortunately, none of these procedures means complete restoration. The treatment is only focused on diminution of frequency and intensity of bleeding (17) .
Duncan et al. treated a patient with severe recurrent epistaxis. Bleomycine was repeatedly injected into the damaged mucosa, there was no episode of epistaxis during the next two years (18) .
Mucosal treatment includes transmucosal injections of fibrin glue or Aetoxisclerol -a sclerosing agent used in phlebology. Haemostatic gels can contribute to the treatment of epistaxis (20) .
The efficacy of endovascular embolization varies from 20% to 80%. The wide variation in the results is presumably due to varying definitions of successful treatment and various length of observation. In patients with HHT we often see the hypertrophy of ethmoid arteries and other collaterals, which is probably the reason of the low efficacy of embolization. Elden et al. recommend endovascular embolization as the last therapeutic option when other possibilities fail (21) .
Ghilezan et al. studied the efficacy of brachytherapy used in 43 patients during 20 years. Regardless of the dosage recurrent epistaxis reappeared approximately two years after the treatment. In four patients septal perforation was formed after brachytherapy (22).
Kim JY et al. used endoscopic cryotherapy for the treatment of recurrent epistaxis due to HHT. Their treatment strategy resulted in successful management of symptoms and no associated complications (9) .
Recently, a case of patient treated with radiofrequency and fibrin sealant was reported. Radiofrequency ablation of telangiectasia is a save, effective and well tolerated technique even in patients who underwent other previous treatments (23).
Fiorella et al. performed septal dermoplasty to 67 patients, the necessity of blood supply was statistically significantly lower (24) . From August 2011 through March 2014 the North American Study of Epistaxis in HHT was performed. There were 121 adult patients suffering from HHT. Patients received twice-daily nose sprays for 12 weeks with either bevacizumab 1% (4 mg/d), estriol 0.1% (0.4 mg/d), tranexamic acid 10% (40 mg/d), or placebo (0.9% saline), there were no significant between-group differences in the use of topical intranasal treatment with bevacizumab vs estriol vs tranexamic acid vs placebo and epistaxis frequency (25) .
The closure of the nasal cavity is an effective but very mutilating way of treatment. After the closure breathing through the nasal cavity is no more possible, the nasal mucosa is not irritated by the inhaled air and pollutants. Lund et al. used this method in group of 100 patients. Overall, most patients derived significant benefit from the procedure with complete cessation of nasal bleeding in 94% of cases. Loss of smell and taste was the most frequent post-operative complaint (26) . This method cannot be used in patients with septal perforation. Wirsching et al. studied the efficacy of temporary nasal occlusion with hypoallergenic tape. In a group of 20 patients, the application of the tape together with Nd:YAG therapy led to stable haemoglobin levels during the study (27) .
Our patient refused surgical treatment, selective endovascular embolization was performed repeatedly. Unfortunately, there was no improvement, the frequency and intensity of epistaxis remained unchanged. The nasal mucosa was damaged, the recurrent epistaxis was always severe, we were led to conclude that any treatment mentioned before would be unsuccessful.
CONCLUSION
Hereditary haemorrhagic telangiectasia is a rare condition, recurrent epistaxis and the bleeding from gastrointestinal tract are the main symptoms, vascular malformations are pathognomonic histological findings. Quality of life is significantly impaired. Unfortunately, there is no causal therapy of HHT. Multiple therapeutic approaches have been tried but they are largely palliative with variable results (8) .
